Sanofi· @sanofi · X·· 2026-06-23精选AI 评分58
AI 导读
赛诺菲宣布，日本厚生劳动省已批准其口服可逆BTK抑制剂，用于治疗对其他治疗难治的成人免疫性血小板减少症（ITP）。该药为日本首个获批用于该适应症的口服可逆BTK抑制剂。
推荐理由
日本批准首个口服可逆BTK抑制剂用于难治性ITP，读者可了解该适应症现有治疗之外的新选择。
正文
#NEWS: The Japan Ministry of Health, Labour and Welfare has approved the first oral, reversible BTK inhibitor to treat adults with immune thrombocytopenia (ITP) who are refractory to other treatments. Read more ⬇️: https://www.sanofi.com/en/media-room/press-releases/2026/2026-06-23-05-15-00-3315701
来源：Sanofi · x.com